SRC and STAT Pathways Journal of Thoracic Oncology

Slides:

Advertisements

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

STAT3 Michael Patel.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Volume 76, Issue 9, Pages (November 2009)

Myeloma cell interaction with extracellular matrix (ECM) and accessory cells in the marrow. Myeloma cells require support from bone marrow stromal cells.

The Kinase-Independent, Second Life of CDK6 in Transcription

Sustaining Proliferative Signaling and Evading Growth Suppressors

Laurent L'homme, PhD, David Dombrowicz, PhD

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Miriam Marqués, Francisco X. Real European Urology

CD5: A New Partner for IL-6

Volume 52, Issue 3, Pages (March 2010)

A Novel ER Stress-Independent Function of the UPR in Angiogenesis

Erythropoietin neuroprotection with traumatic brain injury

Figure 1 A schematic representation of the HER2 signalling pathway

Signaling molecules as therapeutic targets in allergic diseases

From mesothelioma to cardiovascular protection via the phosphoinositide-3 kinase pathway: A new vista in cardiothoracic surgery Igor E. Konstantinov,

Volume 56, Issue 3, Pages (March 2012)

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

Volume 143, Issue 2, Pages (November 2016)

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

A Novel ER Stress-Independent Function of the UPR in Angiogenesis

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Theresa A. Reno, PhD, Jae Y. Kim, MD, Dan J. Raz, MD

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Apoptosis-targeted therapies for cancer

Hedgehog Signaling Pathway and Lung Cancer

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

TGF-² Signaling Pathway in Lung Adenocarcinoma Invasion

Shannon Otsuka, BSc, Gwyn Bebb, BMBCh, PhD, FRCPC

Michael G. Katz, MD, PhD, Anthony S. Fargnoli, PhD, Andrew P

Vascular Endothelial Growth Factor (VEGF) Pathway

FGFR Signaling as a Target for Lung Cancer Therapy

Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405.

Olga C. J. Schuurbiers, MD, Johannes H. A. M

Volume 76, Issue 9, Pages (November 2009)

Met as a therapeutic target in HCC: Facts and hopes

ID Proteins Regulate Diverse Aspects of Cancer Progression and Provide Novel Therapeutic Opportunities Radhika Nair, Wee Siang Teo, Vivek Mittal, Alexander.

Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…

Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non- small Cell Lung Cancer Tomofumi Yohena, MD, Ichiro Yoshino, MD,

Volume 73, Issue 1, Pages 5-7 (January 2008)

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

The RAS/MAPK Axis Gets Stressed Out

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

CDK Inhibitors: Cell Cycle Regulators and Beyond

Death receptor-mediated apoptosis and the liver

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Erratum Journal of Thoracic Oncology

Signalling links in the liver: Knitting SOCS with fat and inflammation

SOCS Proteins, Regulators of Intracellular Signaling

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Apoptosis-targeted therapies for cancer

Jair Bar, MD, PhD, Glenwood D. Goss, MD, FCPSA, FRCPC

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

GPC5 Gene and Its Related Pathways in Lung Cancer

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Figure 2 Signalling downstream of the IL-6 receptor

Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases Xiaoyu Hu, Lionel B. Ivashkiv Immunity

Characterization of the MM.1 human multiple myeloma (MM) cell lines

Overview of molecular JAK signaling.

Predicting Risk of Radiation-Induced Lung Injury

Presentation transcript:

SRC and STAT Pathways Journal of Thoracic Oncology Eric B. Haura, MD Journal of Thoracic Oncology Volume 1, Issue 5, Pages 403-405 (June 2006) DOI: 10.1016/S1556-0864(15)31601-4 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Ligand-dependent activation of cell surface receptor tyrosine kinases, such as EGFR, results in receptor dimerization, autophosphorylation, and recruitment of accessory non-receptor tyrosine kinases such as SRC and JAK family members. SRC family proteins (left lower inset) can activate a number of downstream proteins through tyrosine phosphorylation. Downstream proteins activated by SRC signaling include p130Cas and FAK (cell adhesion and invasion), PI3K/Akt (cell survival), and VEGF and HIF1α (angiogenesis). SRC signaling can also regulate cell cycle proteins such as c-Myc, cyclin D, and p21 through transcriptional and post-translational mechanisms. Tyrosine kinase activity of EGFR, SRC, and JAK proteins leads to tyrosine phosphorylation of Stat3 monomers, dimer formation, nuclear translocation, DNA binding, and transcription of Stat3-dependent genes (right lower inset). Activated Stat3 up-regulates a number of genes involved in the hallmarks of cancers, such as vascular endothelial growth factor (VEGF) and hypoxia inducible factor 1 α (HIF1α) (angiogenesis), c-Myc and cyclin D1 (cell cycle progression), and matrix metalloproteinases such as MMP2 and MMP9 (invasion). Stat3 plays a major role in controlling tumor cell survival by up-regulating Bcl-2 survival genes (Bcl-2, Bcl-xL, Mcl-1), the IAP member survivin, and Akt1 while repressing pro-death genes TRAIL and p53. Stat3 activates SOCS3 that negatively regulates JAK activity and hence is a negative feedback mechanism for Stat3 activation. Journal of Thoracic Oncology 2006 1, 403-405DOI: (10.1016/S1556-0864(15)31601-4) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions